Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $33.5909.

Several analysts have recently commented on ROIV shares. Sanford C. Bernstein started coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 price target on the stock. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. Guggenheim raised their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Finally, TD Cowen raised their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $28.70 on Thursday. The stock’s fifty day moving average is $28.68 and its 200-day moving average is $25.59. The stock has a market capitalization of $20.64 billion, a PE ratio of -47.83 and a beta of 1.13. Roivant Sciences has a 52 week low of $10.70 and a 52 week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the prior year, the business earned ($0.29) earnings per share. As a group, analysts forecast that Roivant Sciences will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the transaction, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew Gline sold 289,774 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the transaction, the chief executive officer owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 945,173 shares of company stock valued at $27,654,456 in the last three months. Insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. TD Asset Management Inc lifted its position in Roivant Sciences by 94.7% in the 3rd quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after acquiring an additional 153,800 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Roivant Sciences in the 3rd quarter valued at $877,000. HighVista Strategies LLC lifted its position in Roivant Sciences by 61.4% in the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock valued at $1,496,000 after acquiring an additional 37,590 shares in the last quarter. Neo Ivy Capital Management lifted its position in Roivant Sciences by 229.6% in the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock valued at $3,592,000 after acquiring an additional 165,362 shares in the last quarter. Finally, Capricorn Fund Managers Ltd lifted its position in Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after acquiring an additional 247,000 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.